Sign in
TerminatedNo phase

Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections

Key facts

Who runs it
Hospital Moinhos de Vento
Where
Brazil29 sites in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
107 people enrolled
Started
27 Jan 2022
Ended
31 Dec 2023
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Duration of therapy
Record updated
6 March 2024
Why it stopped
low recruitment rate

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Infection's diagnosis while in the ICU
  • Severe infection in any site (defined as the presence of sepsis/septic shock or bloodstream infection or pneumonia) associated with a positive culture by MRD-GNB (Acinetobacter baumannii complex, Pseudomonas aeruginosa, and Enterobacterales bacteria, only susceptible to carbapenems and/or polymyxins)
  • Hemodynamically stable and afebrile (axillary temperature less than 37.8ºC) for at least 48 hours on day 7 of adequate antibiotic therapy
  • Consent of the team providing care to the patient regarding their inclusion in the research

Who cannot take part

  • Inclusion in other experimental studies involving antimicrobial therapy
  • Positive blood cultures for the same pathogen within 48 hours prior to randomization, when collected
  • Uncontrolled concomitant infection with another GNB (regardless of susceptibility profile)
  • Previous inclusion in this study
  • Infections that have as the primary site: endocarditis/endovascular infection, necrotizing fasciitis, osteomyelitis, abdominal abscess or other abdominal infections requiring surgical intervention (except infections that have been treated surgically, with curative character within the first 3 days of appropriate antimicrobial therapy), central nervous system Infections, empyema, prosthetic infection
  • Immunosuppression defined as: neutrophil cells <1000/mm³ in the current hospitalization, HIV/AIDS diagnosis with last CD4 count <200/mm³, solid organ transplantation in the last year and/or need for increased immunosuppression due to acute rejection in the last year, hematopoietic stem cell transplantation in the last year, and/or current therapy for chronic graft-versus-host disease
  • Known pregnancy
  • Patient in palliative care who has already decided not to restart antimicrobials, if necessary, or hemodynamic support measures

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Antimicrobial resistance is a major global problem, particularly in hospital-acquired infections (HAIs). Gram-negative bacilli (GNB), including Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii, are among the most common pathogens associated with multidrug resistance and HAIs. These bacteria are of special concern because few therapeutic options are available.

Read full original descriptionShow less

Traditionally, the duration of treatment for severe multidrug-resistant (MDR)-GNB infections is 14 days. Studies of severe infections by GNB, regardless of susceptibility profile, have shown that shorter antimicrobial treatments are not inferior to traditional durations of therapy and are associated with a lower incidence of adverse effects. However, there are currently no studies assessing whether shorter duration of antimicrobial treatment is effective for MDR-GNB.

This open-label, randomized clinical trial aims to assess the non-inferiority of 7-day antibiotic therapy compared to conventional 14-day treatment in severe infections by MDR-GNB.

The 2 groups in the trial

  • 7-day adequate antibiotic therapyTreatment being tested

    Adequate antibiotic therapy is defined as antimicrobial treatment with at least one agent with in vitro susceptibility.

    Treatment: Duration of therapy

  • 14-day adequate antibiotic therapyExisting treatment, for comparison

    Adequate antibiotic therapy is defined as antimicrobial treatment with at least one agent with in vitro susceptibility.

    Treatment: Duration of therapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Open-label, Randomized Clinical Trial to Assess the Non-inferiority of 7-day Antibiotic Therapy Compared to Conventional 14-day Treatment in Multidrug-resistant Gram-negative Bacilli Infections
Record updated
6 March 2024